Consequently, PIT against BC could be extended to other therapeutic antibodies currently being evaluated in clinical trials, e.g., ACDs directed against human epidermal growth factor receptor 2 (HER-2), tissue factor (TF), or epithelial cell adhesion molecule (EpCAM) [32]. This evidence concerns the gene ERBB2 and breast cancer.